idiopathic pulmonary fibrosis

News

Pulmonary fibrosis drug developer Avalyn files IPO

Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.

News

Insilico ends 2025 with $293m Hong Kong IPO

One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.

News

Boehringer bags FDA okay for new pulmonary fibrosis drug

Boehringer's successor to blockbuster IPF therapy Ofev has been approved by the FDA as Jascayd, but will the new drug be a commercial success?

News

PureTech launches lung disease specialist Celea

PureTech launches Celea Therapeutics, tasked with bringing forward a drug that could offer a 'step change' in pulmonary fibrosis treatment.

News

Pliant slumps on decision to pause lung disease drug trial

Shares in Pliant plunged after the US biotech revealed that a safety signal led it to pause a trial of its idiopathic pulmonary fibrosis drug.

News

Trial sets up filings for Boehringer IPF drug nerandomilast

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O

Pulmonary fibrosis drug developer Avalyn files IPO

Insilico ends 2025 with $293m Hong Kong IPO

Boehringer bags FDA okay for new pulmonary fibrosis drug

PureTech launches lung disease specialist Celea

Pliant slumps on decision to pause lung disease drug trial

Trial sets up filings for Boehringer IPF drug nerandomilast

Avalyn seeks $300m from its IPO

Discover a new era of healthcare panel engagement: Grounded ...

idiopathic pulmonary fibrosis

Editor's Picks